Open AccessTesting Topical Products Specifically to Reduce Inflammatory Pain from Gout: Transdermal NSAID Delivery and Monosodium Urate Solubility
Author(s) -
Mark W. Hooper,
He Li
Publication year - 2022
Publication title -
journal of pain research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.888
H-Index - 49
ISSN - 1178-7090
DOI - 10.2147/jpr.s367536
Subject(s) - solubility , ibuprofen , transdermal , medicine , gout , diclofenac , diclofenac sodium , pharmacology , drug , permeation , chromatography , chemistry , biochemistry , organic chemistry , membrane
Gout is caused by crystals of monosodium urate (MSU) in the joints. Topical nonsteroidal anti-inflammatory drug products (NSAIDs) are often the first-choice immediate treatment. This study examined the effect of commercially available and newly developed transdermal NSAID products on the solubility of MSU in a physiologically relevant system, alongside the efficacy of transdermal NSAID delivery.